Mark Elliott Boulding sold $4.0M of PTCT
EXEC. VP AND CLO at PTC THERAPEUTICS, INC.. 75,420 shares at an average of $53.08, traded Mar 10, 2025, filed Mar 12, 2025.
Score components
- +15RoleOfficer
- +25Trade size$4.0M at market
- +20Share of holdings soldSold 51% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-007856, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 10, 2025 | MOption exercise Common Stock10b5-1 | +45,392 | $33.02 | $1.5M | 149,293 | Mar 12, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stock10b5-1 | -45,392 | $53.15 | $2.4M | 103,901 | Mar 12, 2025 |
| Mar 10, 2025 | MOption exercise Common Stock10b5-1 | +11,398 | $33.02 | $376k | 115,299 | Mar 12, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stock10b5-1 | -11,398 | $53.12 | $605k | 103,901 | Mar 12, 2025 |
| Mar 10, 2025 | MOption exercise Common Stock10b5-1 | +11,249 | $25.69 | $289k | 115,150 | Mar 12, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stock10b5-1 | -3,487 | $52.24 | $182k | 111,663 | Mar 12, 2025 |
| Mar 10, 2025 | SOpen-market sale Common Stock10b5-1 | -7,762 | $53.05 | $412k | 103,901 | Mar 12, 2025 |
| Mar 11, 2025 | MOption exercise Common Stock10b5-1 | +5,662 | $33.02 | $187k | 109,563 | Mar 12, 2025 |
| Mar 11, 2025 | SOpen-market sale Common Stock10b5-1 | -5,662 | $53.02 | $300k | 103,901 | Mar 12, 2025 |
| Mar 11, 2025 | MOption exercise Common Stock10b5-1 | +1,719 | $33.02 | $57k | 105,620 | Mar 12, 2025 |
| Mar 11, 2025 | SOpen-market sale Common Stock10b5-1 | -1,719 | $53.01 | $91k | 103,901 | Mar 12, 2025 |
| Mar 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -45,392 | $0.00 | $0 | 18,788 | Mar 12, 2025 |
| Mar 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,398 | $0.00 | $0 | 4,114 | Mar 12, 2025 |
| Mar 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,249 | $0.00 | $0 | 33,751 | Mar 12, 2025 |
| Mar 11, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,662 | $0.00 | $0 | 13,126 | Mar 12, 2025 |
| Mar 11, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,719 | $0.00 | $0 | 2,395 | Mar 12, 2025 |
Related signals
Other insiders at PTC THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $158k 2,500 shares | -0% | |
| 6Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $133k 2,073 shares | -2% | |
| 27Weak | PTC THERAPEUTICS, INC. | Glenn Steele Jr Md Phd director | $782k 12,000 shares | -35% | |
| 28Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.3M 20,000 shares | -2% | |
| 20Weak | PTC THERAPEUTICS, INC. | Michael Schmertzler director | $1.4M 20,000 shares | -1% | |
| 30Weak | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $2.9M 35,572 shares | -35% | |
| 40Moderate | PTC THERAPEUTICS, INC. | Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER | $6.0M 71,928 shares | -70% | |
| 40Moderate | PTC THERAPEUTICS, INC. | Allan Steven Jacobson director | $2.1M 26,000 shares | -112% | |
| 7Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $214k 2,812 shares | -3% | |
| 7Weak | PTC THERAPEUTICS, INC. | Mark Elliott Boulding EXEC. VP AND CLO | $214k 3,375 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.